Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Haemorrhagic events
[66] RCT 3-armed trial	279 people, 70% with New York Heart Association (NYHA) functional class III In review [65]	Rate of haemorrhagic events mean follow-up of 27 months with warfarin (international normalised ratio [INR] 2.5) with no antithrombotic treatment
[67] RCT	197 people aged 20 to 75 years with NYHA class II to IV caused by either previous MI or idiopathic dilated cardiomyopathy	Haemorrhagic event rate mean follow-up of 27 months 4.6/100 patient-years with warfarin 0/100 patient-years with placebo	Significance not assessed